AI-powered CT analysis for respiratory clinical trials
Thirona provides advanced AI-powered quantitative analysis of chest CT scans, supporting pharmaceutical companies in accelerating respiratory drug development across clinical trial phases.
Quantitative CT analyses and treatment efficacy assessment
With advanced, extensively validated anatomical segmentation and quantification methods, Thirona’s LungQ® analyses deliver precise measurements of anatomical lung structures, including parenchyma, airways and vasculature.
Enabling detailed local assessment of lung conditions such as emphysema, air trapping, bronchial dilatation, mucus plugging, and other clinically relevant features, the objective data generated by Artificial Intelligence, can help significantly improve trial efficiency and strengthen regulatory approval process.
- In Phase I and II trials, AI-powered image analysis can help detect early treatment signals and refine patient selection.
- In Phase III and IV, it may offer more precise efficacy assessments and support long-term disease monitoring.
Thirona’s therapeutic areas of expertise cover all major lung diseases, including:
- COPD
- Severe Asthma
- Cystic Fibrosis
- Bronchiectasis disease
- ILD
Examples of LungQ® AI analyses
Emphysema severity
Chronic perfusion defect
Bronchial wall thickening
Mucus plugs
Robust clinical research evidence
With more than 200 scientific publications and 24,000 patients analyzed in cohort studies and randomized controlled trials across diseases, Thirona’s AI analyses are backed by extensive clinical evidence, demonstrating consistently high performance in real-world settings.
See the list of publications.
Featured talk
Advancing Bronchiectasis Clinical Trials with AI-powered Image Analysis
Prof. Harm Tiddens, MD, PhD — Chief Medical Officer, Thirona
